Learn About The 2020 Novel Coronavirus (2019-nCoV) Outbreak

OSUWexnerbloglogo2014Learn About The 2020 Novel Coronavirus (2019-nCoV) Outbreak. On this CME webcast, Today, we’re bringing you a special edition of OSU MedNet in order to update you about the recent outbreak of a novel coronavirus that has been named 2019-nCoV. Joining our moderator, Dr. Jim Allen, as a presenter is infectious disease specialist and Clinical Instructor in Internal Medicine, Dr. Michael Haden.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: UNDERSTAND the route of spread of 2019-nCoV; and UNDERSTAND isolation and testing recommendations for 2019-nCoV.

You’ll also learn about the following:

  • Coronaviruses
  • When should you suspect 2019-nCoV
  • CDC recommendations
  • Testing for 2019-nCoV:
  • Treatment

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

On-line Education Provides Understanding of Suboxone Treatment

OSUWexnerbloglogo2014 On-line Education Provides Understanding of Suboxone Treatment. On this CME webcast, we are going to examine how buprenorphine and Suboxone fit into the management of the opioid-addicted patient in the hospital. To tell us how this works in the emergency department is Assistant Professor of Internal Medicine and Emergency Medicine, Dr. Emily Kauffman. And to tell us about medication assisted treatment for inpatients is hospitalist and Assistant Professor of Internal Medicine, Dr. Margaret Williams.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: EXPLAIN why Medications-Assisted Treatment (MAT), specifically buprenorphine (suboxone) is effective for treatment of Opioid Use Disorder; DESCRIBE the importance of addressing opioid use disorder in all patient encounters, beginning with the Emergency Department.

You’ll also learn about the following:

  • The role of the emergency department in treating opioid addiction
  • The role of medication assisted therapy in hospitalized patients
  • Project DAWN
  • RREACT
  • Management of opioid-dependent patients who are NPO
  • DEA-X waivers

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Learn About New Treatments for Osteoporosis

OSUWexnerbloglogo2014 Learn About New Treatments for Osteoporosis. On this CME webcast, we’re going to bring you up to date on the latest recommendations for the management of osteoporosis and on the latest developments in pharmacologic treatment. Joining our moderator in the studio is endocrinologist and Associate Professor of Internal Medicine, Dr. Steven Ing. And endocrinologist and also Associate Professor of Internal Medicine, Dr. Laura Ryan.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DISCUSS 2017 ACP guidelines on osteoporosis; DISCUSS studies subsequent to guidelines; UNDERSTAND the latest data on therapy for postmenopausal osteoporosis using evidence based clinical studies; and IMPROVE comfort in deciding on initial therapy to choose for patients at high risk for fracture, then monitoring that choice over time.

You’ll also learn about the following:

  • New developments in osteoporosis treatment
  • Choosing a bisphosphonate
  • Calcium & vitamin D

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Managing Complications of Chemotherapy Discussed on CME Webcast

OSUWexnerbloglogo2014 Managing Complications of Chemotherapy Discussed on CME Webcast. On this CME webcast, to update us is medical oncologist and Associate Professor of Internal Medicine from the Ohio State University and the James Cancer Hospital, Dr. Erin Bertino. And also from the James Cancer Hospital, Assistant Professor of Internal Medicine, Dr. Edmund Folefac.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: RECOGNIZE the differences in toxicity for three categories of oncology therapy: cytotoxic chemotherapy, targeted therapy, and immunotherapy; and UNDERSTAND basic management of the most common toxicities of chemotherapy, targeted therapy, and immunotherapy.

You’ll also learn about the following:

  • Evolution of targeted therapies and immunotherapy
  • What to expect with cancer treatment

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

CME Webcast Teaches on Preventive Cardiology

OSUWexnerbloglogo2014 CME Webcast Teaches on Preventive Cardiology. The best way to improve outcomes in cardiovascular disease is to not get it in the first place and today on MedNet21, we are going to show you what you can do to prevent heart disease in your patients. Let me welcome today’s guests. Dr. Wesley Milks is a cardiologist and Assistant Professor of Internal Medicine and Kelly Bartsch is a pharmacist specializing in lipid management.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: REVIEW
the mechanisms of action of the major medication classes utilized in the 2018 multi-society cholesterol guidelines; and UNDERSTAND the influence of the new cardiovascular outcomes trials for ezetimibe and the PCSK9 inhibitors on the new cholesterol guidelines; DEMONSTRATE understanding of key atherosclerotic risk and risk-enhancing factors as well as of recent pivotal lipid lowering treatment guidelines; and SELECT the appropriate target of lipid lowering therapy (e.g. LDL-C or non-HDL-C) with respect to the patient’s comorbid metabolic conditions.

You’ll also learn about the following:

  • Cholesterol level goals
  • Indications for medical treatment of lipids
  • Follow-up of patients started on cholesterol lowering drugs
  • Monitoring of cholesterol lowering drugs
  • CRP and other inflammatory markers

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.